SYHA1813 for returning or worsening aggressive brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called SYHA1813 for meningiomas (tumors in the brain's protective lining) that have come back or are growing after surgery and radiation. The goal is to see if this drug can help slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed high-grade meningioma (WHO grade II or III) that has returned or is getting worse
- You've already had surgery and radiation therapy for your meningioma
- You have at least one tumor that can be measured on an MRI scan
- Your overall health and functional ability are reasonably good (KPS score of 60 or higher—meaning you can do light activities)
- Your doctors expect you to survive at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYHA1813 for people with high-grade meningioma that has come back or is growing despite previous treatment. The goal is to see if the drug can shrink or slow down the tumor.
This trial tests a new medicine called SYHA1813, alone or combined with other treatments, for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if it is safe and if it can help shrink or control the tumors.
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
This trial tests a new drug (SHR-A1811) combined with radiation therapy for people with HER2-positive or HER2-low breast cancer that has spread to the brain. It aims to see if the combination can better control brain metastases.
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
This trial tests a new drug, MT027, for people with high-grade glioma (a type of brain tumor) that has come back or continued to grow after standard treatment. The drug targets a protein called B7-H3 found on tumor cells. The goal is to see if it can help shrink tumors or slow the disease.
Hear when a new High Grade Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.